Immunotherapy has quickly become a standard treatment option for patients with a number of tumor types, such as lung, bladder and kidney cancers, and the reach of immuno-oncology is spreading. But none of the current checkpoint inhibitors have proven effective in treating glioblastoma, a deadly form of cancer with few current treatment options and a poor survival rate.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?